Measurements of the thickness of the eye’s retina — the layer of nerve cells lining the back of the eye — could be used to predict disability progression and relapses in people with multiple sclerosis (MS), a real-world study from Austria suggests. “Our study shows that both crossectional and…

The pandemic notwithstanding, MS Run the US has fielded 18 runners — including eight with multiple sclerosis (MS) — to traverse the United States to raise awareness and funds to support MS research and to aid those living with disability caused by the neurodegenerative disease. The organization’s Ultra…

Abnormalities detected on MRI scans at the onset and within the first two years of disease may predict disability worsening in children with multiple sclerosis (MS), a nine-year study reports. Specifically, damage in the spinal cord, brain, and optic nerve plays a major role in predicting outcomes in these…

People with multiple sclerosis (MS) who have more extensive mobility issues are more likely to have worse outcomes from COVID-19, a new study indicates. The study findings also indicate that COVID-19-associated outcomes are worse among MS patients who are Black, older, have heart-related diseases, and who were treated with…

Treatment of up to a year with memantine — an approved therapy for Alzheimer’s disease — failed to prevent cognitive decline and disability, and to significantly reduce fatigue and spasticity in adults with multiple sclerosis (MS), a review of published studies shows. The therapy, sold under the brand name Namenda, works…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. While researchers make progress in pinpointing markers of disease progression in multiple sclerosis (MS), identifying those that signal…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Cognitive impairment without physical disability in multiple sclerosis (MS) may grow in prevalence as newer therapies better control…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Clinical characteristics of multiple sclerosis (MS) patients, including their response to therapies, vary based on race and ethnicity,…

GeNeuro has completed patient enrollment in its ProTEct-MS Phase 2 clinical trial evaluating temelimab as a treatment for multiple sclerosis (MS), the company announced. The study (NCT04480307), taking place at the Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm, Sweden, has enrolled 42 people with relapsing MS whose…

New Zealand will expand patient access to a list of funded treatments for multiple sclerosis (MS), starting on March 1. The government health agency, PHARMAC, will extend eligibility criteria to include MS patients with expanded disability status scale (EDSS) scores ranging from zero to six. EDSS is a validated…

“Open Circle Chat!”  Have you seen the reality TV series “The Circle”? It was first shown in the U.K. on Channel 4, and there’s now a U.S. version on Netflix. It is well worth a watch.  I started watching it because of the psychological…

Asymptomatic damage to spinal nerves occurs even in clinically stable cases of multiple sclerosis (MS) and carries an increased risk for further lesions, a recent study suggests. Although a firm link between the asymptomatic loss of myelin in the spine and worsening disability remains to be found, this work…

Age is a main driver of disability in multiple sclerosis (MS) and has a key influence on patients’ therapeutic responses to Tecfidera (dimethyl fumarate) and Tysabri (natalizumab), a study showed. Given those findings, age should be considered in the risk/benefit assessment that’s used in the decision-making process for…

Changes in the amount of grey matter in specific regions of the brain appear to occur early in relapsing multiple sclerosis (MS), while structural changes in white matter happen late in disease progression. These were among the findings of a recent study that tracked the sequence of events in…

Long-term use of disease-modifying therapies (DMTs) in people with relapsing-remitting multiple sclerosis (RRMS) has a beneficial cumulative effect compared to shorter treatments, delaying the development of irreversible disability and conversion to secondary progressive MS (SPMS), a recent study…

Levels of myelin sheath components called ceramides are altered in the blood of people with multiple sclerosis (MS) and may be linked with retinal degeneration and physical disability, a study has found.  Specific ceramides were altered only in those with progressive…

People with multiple sclerosis (MS) tend to mentally overestimate the time required to complete a short walking activity, causing cognitive fatigue that may affect their quality of life, a study reports. The connection between cognitive fatigue and imagined motor exercises may offer a potential…

Despite having more severe first and second relapses, children with relapsing-remitting multiple sclerosis (RRMS) tend to recover better than adults with the disease, according to a study. Better recovery in children may be linked to the activation of genes that, in turn, impair the activation of immune cells driving…

Adolescents with multiple sclerosis (MS) have lower levels of fitness compared with healthy teenagers of the same age and a sex, a study suggests. Findings also demonstrated that among younger MS patients, higher levels of fitness were associated with lower disease activity and disability. The study “Youth with…

Disability, fatigue, depression, cognitive impairment, and unemployment are primary risk factors for a poor quality of life in people with multiple sclerosis (MS), according to a recent review study. Conversely, higher self-esteem, self-efficacy, resilience, and social support were identified as protective factors for quality of life (QoL).

The expansion of chronic white matter lesions in people with relapsing-remitting multiple sclerosis (RRMS) determined the increase in total lesion volume and significantly contributed to disease progression, a study has revealed. The study, “Expansion of chronic…

Women who have never given birth are more likely to develop early onset of progressive multiple sclerosis, according to a new study, which also found that a woman’s number of pregnancies showed a positive effect in delaying the disease. In addition, entering menopause earlier, before the age of 46,…

Marked differences in disease characteristics are observed between male and female patients with multiple sclerosis (MS) but they are more pronounced when comparing patients across clinical subtypes, a new study finds. The analysis found that although women are more prone to…

The brain volume of people with relapsing-remitting multiple sclerosis (RRMS) undergoes a dynamic cycle of enlargement and contractions, a new study shows. Patients with a lower volume (contractions) had less severe MS and a shorter disease duration, the study found. Overall, these findings suggest that frequent monitoring of the…

MD1003, MedDay Pharmaceuticals’ high-dose biotin therapy, failed to significantly improve functional ability or walking speed in people with non-active progressive multiple sclerosis (MS), according to data from a Phase 3 clinical trial. Besides failing to meet the trial’s goals, the therapy was associated with inaccurate results in…

Biogen is discontinuing the clinical development of opicinumab, its experimental treatment candidate for multiple sclerosis (MS), based on data from the Phase 2 AFFINITY clinical trial. The announcement, amid a third-quarter report, indicated that the study failed to meet both its main and secondary goals, without further details. The trial,…

Prior treatment with disease-modifying therapies (DMTs) does not affect the long-term benefits of Aubagio (teriflunomide) in treating relapsing forms of multiple sclerosis (MS), according to a review study. The study, “Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis,”…

Long-term treatment with Tecfidera (dimethyl fumarate) continues to be safe and effective at reducing the frequency of relapses and disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), according to 13-year data from a Phase 3 extension study. The study findings were presented at MSVirtual2020 by Ralf…

Continuous treatment with Aubagio (teriflunomide) can safely lower the risk of relapses and disability progression in children with relapsing forms of multiple sclerosis (MS), according to interim data from the open-label extension of a Phase 3 trial. These findings were detailed at MSVirtual2020 by Tanuja Chitnis, MD,…

Low doses of rituximab, an anti-inflammatory medication used off-label to treat multiple sclerosis (MS), are safer and as effective as higher doses at reducing the frequency of relapses and the number of MS lesions, a clinical study shows. The study findings were presented at MSVirtual2020 by Luciana…